Eupraxia Pharmaceuticals (EPRX) Income Statement: Revenue & Earnings

Eupraxia Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Eupraxia Pharmaceuticals Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.24	0.00	0.00	0.00	0.00
Gross Profit	-0.24	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	21.83	20.36	13.63	7.58	0.67
Selling, General & Administrative	14.92	7.48	3.99	6.48	1.00
Operating Expenses	36.76	27.85	17.62	14.15	1.76
Operating Income	-36.99	-27.85	-17.62	-14.15	-1.76
Other Income/Expense
Interest Income	1.59	0.86	0.43	0.05	0.00
Interest Expense	1.31	-1.17	-0.98	-0.97	-1.48
Other Income/Expense	1.73	-0.84	-1.06	-4.74	0.10
Income
Income Before Tax	-35.27	-28.93	-18.99	-19.23	-3.15
Income Tax Expense	0.00	0.04	0.00	0.00	0.00
Net Income	-34.94	-28.22	-18.49	-18.93	-3.14
Net Income - Continuous Operations	-34.94	-28.97	-18.99	-18.33	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-33.72	-27.73	-17.51	-14.11	-1.73
EBIT	-27.00	-27.85	-17.62	-14.15	-1.76
Depreciation & Amortization	0.24	0.11	0.11	0.04	0.03
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-2.00	-1.00
Diluted EPS	-1.00	-1.00	-1.00	-2.00	-1.00
Basic Shares Outstanding	33.93	24.15	19.29	12.41	6.12
Diluted Shares Outstanding	33.93	24.15	19.29	12.41	6.12